Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases
This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.
1. An isolated polypeptide comprising the amino acid sequence of any one of SEQ ID NOs:4-7.
2. The isolated polypeptide of claim 1 , wherein the polypeptide comprises SEQ ID NO:4.
3. The isolated polypeptide of claim 1 , wherein the polypeptide comprises SEQ ID NO:5.
4. The isolated polypeptide of claim 1 , wherein the polypeptide comprises SEQ ID NO:6.
5. The isolated polypeptide of claim 1 , wherein the polypeptide comprises SEQ ID NO:7.
6. A pharmaceutical composition comprising as its active ingredient, a purified polypeptide according to claim 1 .
7. The pharmaceutical composition of claim 6 , wherein the polypeptide comprises SEQ ID NO:4.
8. The pharmaceutical composition of claim 6 , wherein the polypeptide comprises SEQ ID NO:5.
9. The pharmaceutical composition of claim 6 , wherein the polypeptide comprises SEQ ID NO:6.
10. The pharmaceutical composition of claim 6 , wherein the polypeptide comprises SEQ ID NO:7.
11. The pharmaceutical composition according to claim 6 wherein said polypeptide has a purity of 90-100%.
12. The pharmaceutical composition of claim 11 , wherein the polypeptide comprises SEQ ID NO:4.
13. The pharmaceutical composition of claim 11 , wherein the polypeptide comprises SEQ ID NO:5.
14. The pharmaceutical composition of claim 11 , wherein the polypeptide comprises SEQ ID NO:6.
15. The pharmaceutical composition of claim 11 , wherein the polypeptide comprises SEQ ID NO:7.
16. A method to treat stroke comprising administering an effective amount of said pharmaceutical composition of claim 6 to a subject in need of the treatment.
17. The method according to claim 16 wherein said effective amount ranges from 0.001-1,000 mg of said polypeptide per dose.
18. A method of activating STAT3 in neural cells comprising administering an effective amount of the pharmaceutical composition of claim 6 to a subject in need of the treatment.
19. The method according to claim 18 wherein said effective amount ranges from 0.001-1,000 mg of said polypeptide per dose.